Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To Da Moon, of course.
We will all share a clod beer in the end.
I think there will be a PR but if there isn't, it is not "all for naught" (note the spelling). They're not worried about pumping the stock. What's important is the fact that the tree fell in the forest, not whether the sound it made is picked up by the news wires.
And look at all those exclamation points. Too much caffeine, I guess.
Exactly.
Aventura Laboratories was formed to hold certain assets that were originally intended to go into MedScience Laboratories. It's a newly formed company, but it won't be a "fake" one. It'll be a new operating subsidiary of AVNE.
Facebook postings are considered public statements. I'm sure there will be a press release on the wires eventually.
It is like a reverse merger where the company being acquired becomes the controlling party of a shell. This transaction is slightly different, but the IEquity people seem not to appreciate the legalities.
You are correct on that score. There has been no reference to IEquity in AVNE's public filings to date.
As AVNE's Facebook page says, AVNE is acquiring Aventura Laboratories from IEquity.
They've put up a new version of that news:
Aventura Equities, Inc. signs Definitive agreement to acquire 100% of the outstanding stock of Aventura Laboratories, Inc. a non - affiliated entity
February 23, 2014-Georgetown S.C.
The Board of Directors of Aventura Equities, Inc. has signed a definitive agreement to acquire all of the outstanding stock of Aventura Laboratories, Inc. from iEquity, Corp.
iEquity Corp creates, acquires and develops companies and projects in the medical cannabis space.Currently, iEquity Corp holds controlling interest and retains intellectual properties and contracts in several medical marijuana companies and related projects.
Aventura Laboratories, Inc. is a California company dedicated to the research and development of medical marijuana products and to license the production and sales of the products to state licensed collectives in California.
As a result of the transaction a new board of directors and management team will direct the operations of the Company after the closing. Specific timing of the closing was not available at the time of this posting.
Like I said, I think it's just IEquity screwing up. I don't think I'd call it "lying."
Remember your guarantee? I guarantee that the AVNE version is correct, from a legal standpoint.
That's because Henry Jan has way too big an ego and way too little regard for facts and the niceties of corporate law. I suggest you rely on AVNE's own public statements, like the one I posted from their Facebook page, rather than what IEquity spews out. There will also be a press release and public filings by AVNE.
LOL, I have enough but unfortunately I wasn't stocking up at .03. OTC Markets says the float is about 3 million, but I know where about two million shares are so that doesn't leave much.
I'm not prepared to speculate on what will be produced or sold and that sort of thing - I'll let you guys do that :). I'm only going to post facts and rebut misstatements and baseless innuendo (I don't mean from you, from others :)).
I'm not sure I understand your question. Are you confused by IEquity's typically incompetent statement on their website? Aventura Equities (AVNE) will actually be the acquirer, not the acquiree. Here is a more correct version of what will be transpiring when the transaction closes (so far, it is only a signed agreement):
Aventura Equities, Inc. signs Definitive agreement to acquire 100% of the outstanding stock of Aventura Laboratories, Inc. a non - affiliated entity
February 23, 2014-Georgetown S.C.
The Board of Directors of Aventura Equities, Inc. has signed a definitive agreement to acquire all of the outstanding stock of Aventura Laboratories, Inc. from iEquity, Corp.
iEquity Corp creates, acquires and develops companies and projects in the medical cannabis space.Currently, iEquity Corp holds controlling interest and retains intellectual properties and contracts in several medical marijuana companies and related projects.
Aventura Laboratories, Inc. is a California company dedicated to the research and development of medical marijuana products and to license the production and sales of the products to state licensed collectives in California.
As a result of the transaction a new board of directors and management team will direct the operations of the Company after the closing. Specific timing of the closing was not available at the time of this posting.
Nope - that is the authorized. Current o/s is less than 60 million, but the 9:1 split will take it into the 500+ million range. That's why they needed to increase the authorized, not to dilute further.
Outstanding shares.
Yes, that's the place. I already quoted one of the relevant portions from the filings. See if you can find it.
You have a lot of homework to do, so you'd better get started. Read AVNE's public filings on OTC Markets, and then figure out why the stock ran from .05 to the .30s in July.
If you keep "guaranteeing" things without doing any research, you will receive the level of respect your lack of research merits.
"On June 20, 2013 the Company entered a confidential "letter of Intent" to acquire certain
business, assets and intellectual properties of a Califomia medical research group. The
group focuses their efforts on certain published properties and patented medical
extraction processes. The Company intends to expand the licensing opportunities of the
acquired assets."
I'm not sure what you think is so remarkable and exclamation-point-worthy about this. Darrell has been involved with AVNE for 6-7 years or longer. When the IEquity people initially expressed interest in AVNE last June or July - which you can see evidence of in AVNE's public filings, by the way - of course they dealt with Darrell. When they needed IR help for their own company, they asked Darrell to help out, which he did for a brief period.
Oh yeah, I know you've been around AVNE for a long time - even longer than I have (4 years), which is kinda hard for me to imagine :). My reply to you was really directed to the newcomers to this board. My point was, there are a lot of public shells out there, so there have to be particular synergies with AVNE that we will all find out about in due time. Can you smoke algae? :)
But AVNE is more than just a shell. Check the website of their operating subsidiary, Renewed World Energies, and then think what marijuana collectives might be able to do with a company that has proprietary technology for growing algae. Maybe it's just daydreaming, but I'm picturing vast fields of weed growing in tanks :)
"Renewed World Energies is a South Carolina based company founded on solid financials and sound science. RWE is pioneering a new era of mass adoption of bio-fuel by launching the first commercially-viable, closed system, automated microalgae production facility in the world. Over the past six years, Tim Tompkins and Richard Armstrong, RWE’s principals, developed a scalable closed system bioreactor for growing algae that is completely automated. Not only is the system able to grow, harvest, and extract oil from microalgae at a remarkably low cost, but the process also captures Carbon via Flue Gas or bottled CO2 providing a highly nutritious livestock feed source."
http://www.rwenergies.com/
A number of other weed stocks have market caps in the hundreds of millions of dollars. I'm not saying that they deserve it, just that this is possible in this market. AVNE has almost no float at present, as you can see from the historical trading. And the guy who was screaming about dilution apparently failed to recognize that the increase in the authorized shares is necessary to accommodate the 9:1 forward split. That is not dilution.
Here's the link to the page where you can see that the filing for the forward split was submitted to the State of Florida last week (2/20). They have a backlog in posting documents but the actual filing should be posted in a day or two.
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail/EntityName/domp-p97000082722-5405fa9f-cd35-4473-9cd7-455718599c3a/aventura%20equities/Page1
Last Event AMENDMENT
Event Date Filed 02/20/2014
Aventura Equities, Inc. signs Definitive agreement to acquire 100% of the outstanding stock of Aventura Laboratories, Inc. a non - affiliated entity
February 23, 2014-Georgetown S.C.
The Board of Directors of Aventura Equities, Inc. has signed a definitive agreement to acquire all of the outstanding stock of Aventura Laboratories, Inc.
Aventura Laboratories, Inc. is a California company dedicated to the research and development of medical marijuana products and to license the production and sales of the products to state licensed collectives in California.
As a result of the transaction a new board of directors and management team will direct the operations of the Company after the closing. Specific timing of the closing was not available at the time of this posting.
Yep, and the stock will probably be suspended and revoked eventually, maybe soon.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=96902661&txt2find=aavg
It appears that AVNE management has a specific deal or deals in mind and the math has already been done. If they were just splitting the stock for some undetermined future purpose, they probably would have picked a round number like 10:1 or even 8:1. I never heard of a 9:1 split before.
Billionaire before billionaire's were very common (I personally know two billionaire's)
Hmmm, Dominion of Melchizedek and "absolutely at sea." Intended, I hope?
I thought he was unable to spell the old Sally Field TV show "Gidget" :)
What's wrong with that? It's the old "i before e before e before i before e before e after c" rule they taught us in school.
You've probably been pining for AVNE ever since you were posting on this board in 2007.
Hey Raw! What brings you here, the similarity between algae-to-oil and plastics-to-oil? That must be it.
Good post. I think it is going to play out somewhat differently, and with one or more straight acquisitions rather than a reverse merger, but this is only the first shoe -- I'm certain that another will drop soon. It's quite clear that someone has been sucking up any available stock in the .30s these past few weeks, so let's wait to see what comes next. In the meantime, here's today's press release. Gotta love gravitas.
PRESS RELEASE
Feb. 13, 2014, 4:49 p.m. EST
Aventura Equities Announces Expanded Corporate Direction and Opportunities
GEORGETOWN, SC, Feb 13, 2014 (Marketwired via COMTEX) -- Aventura Equities, Inc.'s (otc pink:AVNE) board of directors has announced that it is going to aggressively seek merger and joint venture partners in a number of business sectors where exciting growth opportunities exist. Richard Armstrong, Chief Executive Officer and director of the Company, stated, "We have been approached by several companies concerning opportunities that we must seriously address and evaluate. Shareholders deserve an opportunity to participate in developing and growing markets that we may have been recently exposed to and we believe may finally give the Company the gravitas it deserves."
The Company has been in discussions since June 2013 with several companies and the boards of directors continue to evaluate the prospects and the ultimate benefits to be derived for the Company shareholders.
As part of the change in direction planned by the board of directors, the Company has also dissolved the joint venture agreement previously announced, between its subsidiary Renewed World Energies and US Fuel Corporation. "The joint venture agreement never progressed satisfactorily and we believe it is in the best interest of the Company to not devote economic or human resources to this endeavor at this time," commented Mr. Armstrong.
Disclaimer: Forward Looking Statements
This release contains statements relating to future results which are forward-looking statements. These statements are not historical facts and are not guaranteed, but instead represent only the good faith belief of AVNE management as of the date of this release. Future events are by their nature inherently uncertain and outside of AVNE's control. It is possible that AVNE's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Forward-looking statements in this release are made pursuant to the safe harbor provisions of securities laws in force as of the date of this release. AVNE does do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Contact:
Richard Armstrong
Chief Executive Officer
803-230-8487
ricka@rwenergies.com
www.rwenergies.com
SOURCE: Aventura Equities, Inc.
(C) 2014 Marketwire L.P. All rights reserved.
By March, I think we'll be hard-pressed to find a Pink Sheet stock that ISN'T a weed play.
"You done"? I guess that means none of the rest of us will have the benefit of your unnecessarily snide and borderline bizarre comments anymore. Oh well....
Thanks for clearing that up! It's great that a service like yours still exists - I signed up for emails so long ago, I didn't remember doing it.
You seem to be missing a lot. First of all, I've followed VODG since the early 2000s when Gary Grobbel introduced it to me before he posted it in the Microcap Kitchen on SI, and I've bought and sold it countless times. Secondly, you seem to be implying that posting "heads up, there may be a promo that will allow everyone to sell stock into a spike" is somehow a bad thing -- really?! One of my "stock friends" here on IHub (who was another member of the Grobbel gang and probably owned VODG at one time, by the way) made tens of thousands of dollars after I tipped him off that MKRS, which he had suffered with for years, was being promoted, and he sold into a ridiculous spike. Information sharing is a positive, not a negative, and I figured that anyone who didn't receive the email I received on VODG would want to know that it had been sent out.
The only thing that now seems to have been incorrect was whether the sender of the email I received was compensated for sending it to me. Since I don't currently own VODG and have plenty of other things to do, I didn't feel that I needed to waste my time figuring out who "pennyheaven.com" is - I assumed that they're a promoter. If they were, it would be noteworthy that THEY did not have a compensation disclaimer on the email (note that I said "disclaimer," not "safe harbor statement" as I would have said if I were referring to the press release). I did not suggest that the company did anything wrong whatsoever. The important information was not whether there was a press release, but that some service was emailing it around to people unsolicited. I don't appreciate being told that "all I had to do" was one thing or another, when it should have been quite clear to you that what I DID do -- and didn't HAVE to do -- was for the good of anyone holding this stock and reading the board.
Isn't the "motive" of this statement obvious? It means that if there's an unexplained price spike (like when MKRS went from .05 to .60 in a couple of hours) you sell into it because once you know the cause, you know that it's unsustainable; if nothing happens, there's no need to do anything.
"No one should miss the chance to sell into any spike, and then buy back lower if you want."
Sorry for the false alarm, guys. I guess I jumped to the "paid promo" conclusion when I saw that email in my inbox -- out of all the stock-related emails I get every day, usually pumping, is pennyheaven really an unpaid service? Seems like it might be. From their website:
"Pennyheaven.com is an information resource site for all those interested in OTCBB, microcap, pennystocks. We are one of the oldest continuing penny stock sites online having first appeared in December 1999 and put out our first list of Top Ten microcaps in January 2000. In 2005 we switched to the Super 7 format and have been beating the major indices every year. - See more at: http://pennyheaven.com/about#sthash.OZdmibir.dpuf"
Hey look, it's a promo. (No disclaimer though.) No one should miss the chance to sell into any spike, and then buy back lower if you want.
Pennyheaven.com gp@pennyheaven.com via google.com
8:19 PM (23 minutes ago)
to me
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
Posted: 11 Feb 2014 11:16 AM PST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.
Vitro Biopharma continues development its stem cell-based products and services for drug discovery. We anticipate commercialization of an initial series of assays during the first half of 2014. These assays will include cell-based toxicology assays and drug discovery assays for new osteoporosis and osteoarthritis drugs. We plan additional expansion of this platform going forward. Together with expanding revenues from biomarker analytic services we anticipate further revenue increases during 2014. Because of these immediate business opportunities, we have decided to delay our merger with Neuromics until our operating losses are narrowed and the combination yields stronger profitability, reduced debt and generally improved financial conditions.
There remain significant regulatory obstacles to adult stem cell transplantation in the United States, e.g., a recent court ruling upheld prior decisions that stem cell transplants will be treated as drugs by the US FDA. However, another approach to utilization of the healing & regenerative effects of stem cells involves activation of endogenous stem cells to differentiate into specific cell types. For example, recombinant human erythropoietin, that stimulates regeneration of red blood cells from hematopoietic stem cells, has been used clinically for 25 years to treat anemia associated with chemotherapy to treat cancer. We are in the planning stages of clinical trials to test mobilization of endogenous stem cells in the treatment of traumatic brain injury and Autism Spectrum Disorders. This is based on substantial pre-clinical research suggesting that activation of certain cellular pathways in combination with epigenetic modulation of select gene expression yields increased proliferation, migration and differentiation of adult stem cells including neural stem cells and MSCs.
Dr. Jim Musick, Vitro Biopharma’s President said, “Adult stem cells continue to gain validation and support for use in various regenerative medicine applications. New research reports add to the growing body of evidence that adult stem cells possess pluripotency, the ability to differentiate into any cell type. This property was once thought to be exclusive to embryonic stem cells. Two current research reports in the journal, Nature show that stress factors induce or select pluripotent differentiation capacity as had been previously demonstrated (http://vitrobiopharma.com/2013/06/28/new-method-to-isolate-pluripotent-stem-cells-from-adult-tissues-implications-for-the-clinical-value-of-adult-stem-cells/). Also, significant prior research during the past 10 years shows that adult stem cells may be induced to pluripotency with properties comparable to iPSCs and embryonic stem cells by expression of a single gene (Oct 3/4) as opposed to the required 4 genes needed to reprogram somatic cells. Vitro Biopharma also conducted research supporting pluripotency induction by Oct 3/4/ expression in MSCs and also has reproduced earlier results showing that cellular stress of human MSCs induced or selected apparent pluripotent cells. We plan to offer these cells for research use in the near future.
While research shows the advanced regenerative properties of adult stem cells, there remain significant obstacles to regulatory approval of adult stem cell transplantation. We are pleased to be involved with an alternative approach that does not require stem cell transplantation. While there are numerous research reports supporting the induction of stem cell differentiation by activation of specific cell signaling pathways, there have been only limited clinical trials of this approach. We are planning Phase II trials to demonstrate pharmacodynamic metrics critical to further studies of this approach. This will involve quantitative measurement of multiple biomarkers selective to cell pathway activation and stem cell activation by developing additional custom panels similar to those being used in our expanding bio-analytical services described above.”
Pete Shuster, Neuromics, Inc, CEO, said, “I am excited about the opportunities we have identified for profitably growing revenue. These opportunities include strategically selling our solutions to Biopharmaceutical firms and Regenerative Medicine Clinics. Our plans call for a minimum of 30% in collective revenue growth over the next 3 years. We are in the process of finalizing a detailed 3 year business plan that will be the blueprint for achieving this aggressive growth goal.”
About Vitro Biopharma
Vitro Diagnostics, Inc. dba VitroBiopharma (OTCQB: VODG; http://www.vitrobiopharma.com/), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharma’s mission is “Harnessing the Power of Cells For The Improvement of Life™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com). Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix®, Inc. (http://www.hemogenix.com/), known as the MSCglo quantitative assay for determination of MSC quality, potency and response to toxic agents.
Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.
About Neuromics, Inc.
Neuromics (http://www.neuromics.com/), located in Minneapolis, MN, is a privately-held, profitable and growing bio-reagents company. The company was initially built by supplying bio-markers to Neuroscience Researchers. Today, Neuromics provides a range of solutions that include markers, growth factors, gene expression analysis tools, apoptosis detection kits, primary cells, stem cells and related media. These solutions are increasingly being used in combinations by customers to help accelerate or improve the process of drug discovery.
No hurry - the spiked prick will wait for up to four hours.